Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes (JANUB48)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Sitagliptin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring sitagliptin, diabetes, apolipoprotein B48 and B100
Eligibility Criteria
Inclusion Criteria:
- Males 18 to 65 years of age.
- Post-menopausal women under age 65 on stable medical therapy for 6 months before the study (the patient should have demonstrated stable lipid panels)
- Women should not be on hormone replacement therapy (no recent starting or stopping)
- Type 2 diabetes as defined by the American Diabetes Association.
- Non-smoker.
- Body mass index between 25.0 and 40.0 kg/m2.
- Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%.
- Baseline fasting plasma glucose < 15.0 mmol/L.
- Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening and week -4.
- Patients having received stable doses of metformin for at least 3 months before randomization.
- Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment.
- Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation.
- Patients having normal thyroid stimulating hormone at screening
Exclusion Criteria:
- Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded.
- Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded.
- Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded.
- Patients taking any other hypoglycemic agent, other than metformin.
- Subjects will be excluded if they have cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.).
- Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
- Individuals with a history of mental instability, drug or alcohol abuse or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study.
- History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study.
- Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation.
- Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g).
- Active or chronic hepatobiliary or hepatic disease. In addition, patients with aspartate aminotransferase or alanine aminotransferase >2 x upper limit of the laboratory reference range will be excluded.
- Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1 >1.5 times control).
- Subjects with hemoglobin >2 x the lower limit of the laboratory reference range will be excluded.
- Patients who are known to have tested positive for human immunodeficiency virus (HIV).
- Patients who are currently enrolled in another clinical study.
- Patients who have used any investigational drug within 30 days of the first clinic visit.
- Congestive heart failure New York Heart Association (NYHA) Class III or IV. Uncontrolled cardiac arrhythmias within 3 months of study entry.
- Uncontrolled diabetes mellitus (HbA1c>8.5%) or other endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.
Sites / Locations
- Laval University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Sitagliptin
Placebo
Arm Description
Sitagliptin 100 mg/d for 6 weeks
Placebo for 6 weeks
Outcomes
Primary Outcome Measures
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period
Secondary Outcome Measures
Measurement of Glucagon-like Peptide-1 by ELISA
Measurement of Glucose
Measurement of Insulin
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period
Full Information
NCT ID
NCT01334229
First Posted
April 11, 2011
Last Updated
March 7, 2016
Sponsor
Laval University
Collaborators
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT01334229
Brief Title
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Acronym
JANUB48
Official Title
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Sitagliptin on the Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and Apolipoprotein B100 in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University
Collaborators
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated improvements in islet function [13]. Although clinical studies to date indicate that fasting lipid levels are minimally affected by DPP-IV inhibitor treatment [14-16], animal studies suggested that DPP-IV inhibition reduce intestinal triglycerides (TG) absorption and apolipoprotein (apo) production [17] and increased chylomicron catabolism [18]. Interestingly, a recent study supporting this hypothesis showed that vildagliptin therapy was able to reduce postprandial intestinal triglyceride-rich lipoproteins (TRL) particles in patients with type 2 diabetes [19]. Recently, our group has reported that sitagliptin treatment significantly reduced plasma apo B-48 and TG concentrations in the postprandial state. Moreover, animal studies showed that sitagliptin decreased intestinal secretion of intestinal apo B-48, mainly by increasing level of glucagon-like peptide (GLP)-1 [20]. Therefore, the present study was designed to examine the effects of sitagliptin on the kinetics of TRL apo B-48 and in patients with type 2 diabetes. A possible reduction in postprandial atherogenic TRL apo B-48-containing lipoprotein levels by sitagliptin would add to therapeutic utility of this DPP-4 inhibitor and suggest the potential to reduce cardiovascular risk in patients with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
sitagliptin, diabetes, apolipoprotein B48 and B100
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin
Arm Type
Experimental
Arm Description
Sitagliptin 100 mg/d for 6 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Sitagliptin 100 mg/d for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for 6 weeks
Primary Outcome Measure Information:
Title
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Measurement of Glucagon-like Peptide-1 by ELISA
Time Frame
6 weeks
Title
Measurement of Glucose
Time Frame
6 weeks
Title
Measurement of Insulin
Time Frame
6 weeks
Title
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period
Time Frame
6 weeks
Title
Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males 18 to 65 years of age.
Post-menopausal women under age 65 on stable medical therapy for 6 months before the study (the patient should have demonstrated stable lipid panels)
Women should not be on hormone replacement therapy (no recent starting or stopping)
Type 2 diabetes as defined by the American Diabetes Association.
Non-smoker.
Body mass index between 25.0 and 40.0 kg/m2.
Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%.
Baseline fasting plasma glucose < 15.0 mmol/L.
Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening and week -4.
Patients having received stable doses of metformin for at least 3 months before randomization.
Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment.
Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation.
Patients having normal thyroid stimulating hormone at screening
Exclusion Criteria:
Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded.
Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded.
Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded.
Patients taking any other hypoglycemic agent, other than metformin.
Subjects will be excluded if they have cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.).
Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
Individuals with a history of mental instability, drug or alcohol abuse or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study.
History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study.
Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation.
Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g).
Active or chronic hepatobiliary or hepatic disease. In addition, patients with aspartate aminotransferase or alanine aminotransferase >2 x upper limit of the laboratory reference range will be excluded.
Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1 >1.5 times control).
Subjects with hemoglobin >2 x the lower limit of the laboratory reference range will be excluded.
Patients who are known to have tested positive for human immunodeficiency virus (HIV).
Patients who are currently enrolled in another clinical study.
Patients who have used any investigational drug within 30 days of the first clinic visit.
Congestive heart failure New York Heart Association (NYHA) Class III or IV. Uncontrolled cardiac arrhythmias within 3 months of study entry.
Uncontrolled diabetes mellitus (HbA1c>8.5%) or other endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Couture, MD, PhD
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laval University
City
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs